Neuraminidase (NA)
Neuraminidase (NA) Informations sur la molécule
| Nom anglais | Neuraminidase | Nombre de médicaments commercialisés | 4 |
| Nombre de médicaments cliniques | 5 | Alias de la cible | Neuraminidase |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Neuraminidase |
| Alias de la cible | Neuraminidase |
| Nombre de médicaments commercialisés | 4 |
| Nombre de médicaments cliniques | 5 |
| Phase de R&D la plus avancée | Approved |
Neuraminidase (NA) Liste de produits
- Attribut
Protein (4)Antibody (1)Kits (1)
- Bibliothèque de produits
En ligne (6)
- Espèces
Influenza A virus (A/Croatia/10136RV/2023) & (A/District of Columbia/27/2023) (1)Mouse (1)Influenza (A/Wisconsin/67/2022) (1)Influenza A virus (A/Victoria/4897/2022) (1)Influenza A virus (Missouri/11/2025) (1)Influenza A virus (Sydney/1359/2024)& (Singapore/GP20238/2024) (1)
- Étiquette
His Tag (3)- (2)His Tag & Avi Tag (1)
- Marqueur
Unconjugated (4)- (1)Biotin-labeled (1)
Ajouter au panier
Quantité totale6
- 1
Neuraminidase (NA)Contexte de la molécule
Influenza, commonly known as 'the flu', is an infectious disease of birds and mammals caused by RNA viruses of the family Orthomyxoviridae, the influenza viruses. The virus is divided into three main types (Influenzavirus A, Influenzavirus B, and Influenzavirus C), which are distinguished by differences in two major internal proteins (hemagglutinin (HA) and neuraminidase (NA), which are the most important targets for the immune system. Hemagglutinin binds to the sialic acid-containing receptors on the surface of host cells during initial infection and at the end of an infectious cycle which makes it a great target for vaccine studies.
Neuraminidase (NA)Alias de la molécule
NA,Neuraminidase
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| CD388 | CD-388; JNJ-0953; CD388 | Phase 3 Clinical | Cidara Therapeutics Inc | Influenza, Human | Details |
| Peramivir Inhalation Solution (Langtian Medical Tech) | Phase 2 Clinical | Langtian Medical Technology (Wuhan) Co Ltd | Influenza A virus infections; Influenza B virus infection | Details | |
| Peramivir Inhalation Solution (广州南鑫药业) | Phase 2 Clinical | Guangzhou Nanxin Pharma Co Ltd | Arthralgia; Cough; Fatigue; Headache; Influenza A virus infections; Influenza B virus infection; Influenza, Human; Musculoskeletal Pain; Nasal Obstruction | Details | |
| Oseltamivir/Pimodivir | Phase 1 Clinical | Johnson & Johnson | Influenza A virus infections | Details | |
| Oseltamivir orally disintegrating tablets(Hefei Industrial Pharma) | HY-100209 | Phase 1 Clinical | Hefei Industrial Pharmaceutical Co Ltd | Influenza A virus infections; Influenza B virus infection | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Laninamivir Octanoate Hydrate | CS-8958; R-118958 | Approved | Daiichi Sankyo Co Ltd | Inavir | Japan | Influenza B virus infection; Influenza A virus infections; Influenza, Human | null | 2010-09-10 | Asthma; Influenza A virus infections; Influenza B virus infection; Influenza, Human | Details |
| Zanamivir | GG-167; GR-121167; GR-121167X; 4-Guanidino-Neu5Ac2en | Approved | Glaxosmithkline Plc | 依乐韦, Relenza | United States | Influenza, Human | Glaxosmithkline Plc | 1999-07-26 | Arthralgia; Dengue; Diabetes Mellitus, Type 2; Influenza, Human; Orthomyxoviridae Infections | Details |
| Oseltamivir Phosphate | Ro-64-0796; RO-640796; GS-4104; EN-241104; RO-640796/002; GS-4104/002; GS-4104-002 | Approved | F. Hoffmann-La Roche Ltd, Gilead Sciences Inc | Tamiflu, Hanmi Flu, 达菲 | Switzerland | Influenza, Human | F. Hoffmann-La Roche Ltd | 1999-09-21 | Influenza A virus infections; Influenza in Birds; Influenza, Human; Kidney Failure, Chronic; Obesity; Purpura, Thrombocytopenic, Idiopathic | Details |
| Peramivir Hydrate | BCX-1812; JNJ-2; S-021812; RWJ-270201 | Approved | Biocryst Pharmaceuticals Inc | Peramiflu, Alpivab, 力纬, Rapiacta, Rapivab, Enpiflu Premix | Japan | Influenza, Human | null | 2010-01-13 | Cough; Fatigue; Fever; Headache; Influenza A virus infections; Influenza B virus infection; Influenza, Human; Myalgia; Nasal Obstruction; Pharyngitis | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques